Prelude Therapeutics Incorporated

NASDAQ: PRLD · Healthcare · Biotechnology

PublicHQ Wilmington, DE · New CastleCIK 0001678660Reports USD

#609 of 1,418 Healthcare companies by revenuetop-quartile growth

EA Score

37D

FH 38DQ 32GM —SS 53

v0.1 · 55/100 weight · provisional

↑ revenue growth (YoY), market scale · ↓ disclosure history, return on equity

Methodology →

Revenue TTM

$22.4M

Rev growth YoY (TTM)

+220.3%

Net income (FY)

-$99.5M

Employees

as of 2026-08-13

Market cap

$326.2M

as of 2026-08-13

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$12.1M$12.1M2025

Net income-$99.5M-$99.5M2025

Operating income-$104.6M-$104.6M2025

Total assets$141.3M$141.3M2025

Liabilities$72.7M$72.7M2025

Equity$68.6M$68.6M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Prelude Therapeutics Incorporated’s revenue?

Prelude Therapeutics Incorporated booked $12.1M in FY2025 revenue, growing 73% year over year — faster than most Healthcare companies we track, at a -819.6% net margin.

Peers · Healthcare

Emmaus Life Sciences, Inc.40D Elutia Inc52D Devonian Health Group Inc.46D Escalon Medical Corp.63C CYIOS Corporation49D BIMI International Medical Inc.——

Neighbors

New Castle →

Marvell Technology, Inc.$8.2B76B+Qnity Electronics, Inc.$4.8B53D Incyte Corporation$5.1B90A DuPont de Nemours, Inc.$6.8B62C InterDigital, Inc.$834.0M84B+SLM Corporation——

Key facts

CEOKrishna Vaddi

SectorHealthcare

IndustryBiotechnology

HeadquartersWilmington, DE

ExchangeNASDAQ: PRLD

Employees79

IPO date2020-09-25

Latest filings

10-Q2026-08-11 8-K2026-08-11 8-K2026-06-10 8-K2026-05-12 10-Q2026-05-12 DEF 14A2026-04-29 8-K2026-04-21 8-K2026-04-20

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.